evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,971 questions · 9,849 findings · 853 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,150 · 11.7%GRADE not reported 3,387 · 34.4%Very low 1,963 · 19.9%Low 1,809 · 18.4%Moderate 1,207 · 12.3%High 333 · 3.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Methylphenidate vs placebo or no intervention

ADHD symptoms · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes ADHD symptoms: all parallel‐group trials and first‐period cross‐over… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate vs placebo or no intervention

Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate vs placebo or no intervention

Adverse events considered non‐serious (penicillin versus doxycycline) · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes proportion of participants with one or more adverse events… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Methylphenidate vs placebo or no intervention

General behaviour: all parallel‐group trials and first‐period cross‐over trials General behaviour rating scales (Teacher‐rated) · Children and adolescents with ADHD

It is very uncertain whether methylphenidate changes general behaviour: all parallel‐group trials and first‐period… compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

Clinical improvement: discharged alive ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

Hospital‐acquired infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).

1 finding from 1 review